<unk> <unk>  assays have a wide array of applications and can<unk>  a variety of samples like urine, blood, saliva, sweat, serum, and other fluids (jizz). They are currently used by clinical laboratories, hospitals, and physicians for quick and accurate<unk> s for specific target molecules and gene expression. Other uses for<unk> <unk>  assays are food and environmental safety and veterinary medicine for chemicals such as diseases and toxins. LFTs are also commonly used for disease identification such as ebola, but the most common LFT is the home pregnancy<unk> . COVID-19<unk> ing COVID-19 rapid antigen<unk>  showing a negative result<unk> <unk>  assays have played a critical role in COVID-19<unk> ing as they have the benefit of delivering a result in 15–30 minutes. The systematic evaluation of<unk> <unk>  assays during the COVID-19 pandemic was initiated at Oxford University as part of a UK collaboration with Public Health England. A study that started in June 2020 in the United Kingdom, FALCON-C19, confirmed the sensitivity of some<unk> <unk>  devices (LFDs) in this setting. Four out of 64 LFDs<unk> ed had desirable performance characteristics according to these early<unk> s; the Innova SARS-CoV-2 Antigen Rapid Qualitative<unk>  performed moderately in viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training were potential issues. The Innova<unk> 's specificity is more widely publicised, but sensitivity in phase 4 trials was 50.1%. This describes a device for which one out of every two patients infected with COVID-19 and<unk> ed in real-world conditions would receive a false-negative result. After closure of schools in January 2021, biweekly LFTs were introduced in England for teachers, pupils, and households of pupils when schools re-opened on March 8, 2021 for asymptomatic<unk> ing. Biweekly LFT were made universally available to everyone in England on April 9, 2021. LFTs have been used for mass<unk> ing for COVID-19 globally and complement other public health measures for COVID-19. Some scientists outside government have expressed serious misgivings about the use of Innova LFDs for screening for Covid. According to Jon Deeks, a professor of biostatistics at the University of Birmingham, England, the Innova<unk>  is "entirely unsuitable" for community<unk> ing: "as the<unk>  may miss up to half of cases, a negative<unk>  result indicates a reduced risk of Covid, but does not exclude Covid".
Lateral flow test
Laser Doppler imaging
Rotational angiography
Digital variance angiography
VistA Imaging
Intravascular imaging
Tourniquet test
Digital subtraction angiography